Relay Therapeutics officer proposes USD 1.81 million sale for Relay Therapeutics stock

Published on 10/14/2026 at 03:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The filing covers 93,153 shares valued at USD 1.81 million on October 6, 2026. H.C. Wainwright set a USD 29.00 target for Relay Therapeutics stock.

Key dates and operating figures

Thomas Catinazzo filed a proposed sale covering 93,153 shares on October 6, 2026.
Second-quarter 2026 revenue was USD 350,000 and net loss was USD 83.71 million.
Relay Therapeutics reported USD 911 million in cash after the second quarter of 2026.
The next reporting date is November 11, 2026.

RLAY, US75943R1023, Illustration mit AI erstellt.

Relay Therapeutics officer Thomas Catinazzo filed a proposed sale covering 93,153 common shares valued at USD 1.81 million on October 6, 2026, according to Stock Titan. The filing identifies the transaction as a proposed Rule 144 sale and lists Nasdaq as the exchange.

Three recent company events

On August 6, 2026, Relay Therapeutics reported second-quarter revenue of USD 350,000, a net loss of USD 83.71 million and diluted earnings per share of minus USD 0.41, as shown by TradingView. On September 16, 2026, management described USD 911 million of cash at the end of the second quarter as sufficient to fund operations into 2029, according to Investing.com. The October 6 filing added a proposed sale of 93,153 shares valued at USD 1.81 million.

What does the cash runway fund?

The September update places three registrational programs at the center of Relay Therapeutics' spending plan: first-line breast cancer, second-line breast cancer and vascular anomalies. The company said it expected an enrollment timeline update for the second-line program by the end of 2026 and planned first-line Phase 3 initiation for early 2027, according to Investing.com. That timeline makes cash usage and clinical execution the key counterweights to the insider-sale headline.

Analyst target and reporting date

Investing.com reported that H.C. Wainwright set a USD 29.00 price target while maintaining a Buy rating. The same report said Citizens set a USD 26.00 target with a Market Outperform rating, while Guggenheim retained a USD 26.00 target and Buy rating. TradingView lists November 11, 2026 as the next reporting date for the third quarter of 2026.

Nasdaq quote and valuation

Relay Therapeutics was last at USD 17.36 on Nasdaq on October 13, 2026 at 4:00 p.m. EDT. That level was USD 3.91 below the USD 21.27 52-week high, a gap of 18.38 percent, while market capitalization stood at USD 3.8 billion.

Market context: Market report S&P 500.